- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05608837
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema (LEOPARD)
Efficacy and Safety of Dexamethasone ophthaLmic Suspension Eye drOps in Uveitic and Post Surgical mAculaR eDema (The LEOPARD Study)
The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01.
Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision.
In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery.
Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.
Study Overview
Status
Intervention / Treatment
Detailed Description
LEOPARD is a prospective, multi-center, single masked, randomized, controlled, study. At least 24 eligible subjects (12 with Uveitic macular edema and 12 with Post surgical macular edema) are to be enrolled in the study. There will be 5 sites and the total treatment period is 24 weeks.
The study will consist of 4 phases: Screening Phase, Loading Phase, Treatment Phase and Follow-up Phase. Subjects will receive their assigned treatments until week 04, get randomized into groups and continue their assigned treatments until week 12. Primary endpoint assessments will be performed at week 12.
From week 12 to week 24, if there is still edema as demonstrated on OCT, subjects will receive treatment based on the retreatment criteria.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Quan D Nguyen, MD, MSc
- Phone Number: 650-725-7245
- Email: leopardme@stanford.edu
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Recruiting
- Retina Vitreous Associates Medical Group
-
Contact:
- LEOPARD Coordinating Center
- Email: leopardme@stanford.edu
-
Los Angeles, California, United States, 90095
- Recruiting
- Stein Eye Institute at UCLA
-
Contact:
- LEOPARD Study Coordinating center
- Email: leopardme@stanford.edu
-
Palo Alto, California, United States, 94303
- Recruiting
- Byers Eye Institute at Stanford
-
Contact:
- LEOPARD Coordinating Center
- Email: leopardme@stanford.edu
-
-
Texas
-
McAllen, Texas, United States, 78503
- Recruiting
- Valley Retina Institute P.A
-
Contact:
- LEOPARD Coordinating Center
- Email: leopardme@stanford.edu
-
Plano, Texas, United States, 75075
- Recruiting
- Texas Retina Associates
-
Contact:
- LEOPARD Coordinating Center
- Email: leopardme@stanford.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older.
- Diagnosis of Uveitic macular edema (UME) or post-surgical macular edema (PSME).
- Can provide written informed consent prior to any study procedure being performed, able and willing to follow all instructions, and attend all study visits.
- UME of less than 1 years in duration or PSME of less than 1 year, with presence of intraretinal and/or subretinal fluid in the study eye, with CST of ≥ 320 µm by SD-OCT at baseline (as measured by the central reading center employing Heidelberg Spectralis spectral domain optical coherence tomography, SD-OCT). Note: Recurrent CME is also eligible if the current episode is of less than 1 year.
- An ETDRS BCVA letter score ≤ 70 (Snellen 20/40) and ≥ 35 (Snellen 20/200) in the study eye at baseline (Visit 2).
- A documented diagnosis of inactive/stable uveitis (for UME) at the screening visit.
- A trial of topical NSAID or topical corticosteroids (for PSME) for at least one consecutive month but less than 3 consecutive months before screening visit with documented treatment failure on SD-OCT or based on investigator's clinical evaluation.
Note: If both eyes are eligible, the eye with the worse BCVA will be selected as the study eye. If both eyes have the same BCVA, the non-dominant eye will be selected.
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria will not be included in the study
- Macular edema considered to be due to a cause other than UME or PSME. An eye is not considered eligible if: (1) the macular edema is considered to be related to diabetes (2) clinical exam and/or OCT suggests that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema, or (3) the macular edema is considered to be related to another condition such as age-related macular degeneration, retinal vein occlusion, or drug toxicity.
- A decrease in BCVA due to causes other than UME or PSME (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, previous vitreoretinal surgery, central serous retinopathy, non-retinal condition, substantial cataract, macular ischemia) that are likely to decrease BCVA by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
- Use of other ophthalmic formulations during the study. However, intraocular pressure (IOP) lowering eye drops are allowed if they become necessary due to increased IOP.
- History of glaucoma and documented glaucomatous optic neuropathy or clinically significant ocular hypertension in the opinion of the investigator, involving an IOP ≥ 25 mmHg on > 3 anti-glaucoma medications in the study eye.
- Any other ocular disease that could cause substantial reduction in BCVA, including retinal detachment, epiretinal membrane, vitreous hemorrhage or fibrosis involving the macula in the study eye, other retinal inflammatory or infectious diseases.
- Active peri-ocular or ocular infection (e.g., blepharitis, keratitis, scleritis, or conjunctivitis).
- History of infectious uveitis.
- High myopia (-8 diopter or more correction) in the study eye.
- Any form of diabetic retinopathy.
- History of increased intraocular pressure with topical steroid therapy.
- Pregnancy/Breastfeeding
For UME:
- Active uveitis as determined by the presence of anterior chamber cells or vitreous cells.
- Unstable (increasing) dose of immunosuppressives during 2 months prior to the baseline visit. Immunosuppressives are defined as antimetabolites (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus, among others) and biologics (including adalimumab, infliximab, tocilizumab, golimumab, secukinumab and rituximab, and others).
- Treated with more than 2 types of immunosuppressives (excluding steroids) within 2 months prior to baseline visit.
- Unstable (increasing) dose of oral prednisone for 1 month before baseline visit.
- Oral prednisone therapy at dose > 10 mg daily (or equivalent) within 1 month prior to baseline visit.
- History of contact lens use within 2 weeks prior to baseline or at any time during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Dose UME - 6 drops OCS-01
From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24. |
One drop of OCS-01 eye drops, 3-6 times daily.
Dosing frequency will depend on the phase of the study.
Other Names:
|
Experimental: Low Dose UME 3 drops OCS-01 and 3 drops Placebo
From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day,( total 6 drops each day) until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24. |
One drop of OCS-01 eye drops, 3-6 times daily.
Dosing frequency will depend on the phase of the study.
Other Names:
|
Experimental: High dose PSME - 6 drops of OCS-01
From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24. |
One drop of OCS-01 eye drops, 3-6 times daily.
Dosing frequency will depend on the phase of the study.
Other Names:
|
Experimental: Low dose PSME - 3 drops of OCS-01 and 3 drops of Placebo
From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day, (total 6 drops each day) until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24. |
One drop of OCS-01 eye drops, 3-6 times daily.
Dosing frequency will depend on the phase of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central Subfield Thickness
Time Frame: Baseline to 12 weeks
|
Mean change in central subfield thickness (CST) on optical coherence tomography (OCT) at week 12 compared to baseline.
|
Baseline to 12 weeks
|
Visual Acuity
Time Frame: Baseline to 12 weeks
|
Mean change in early treatment of diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) letter score at week 12
|
Baseline to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in visual acuity
Time Frame: Baseline to 24 weeks
|
Mean change in ETDRS BCVA letters at weeks 2, 4, 6, 8, 16, 20 and 24 compared to baseline.
|
Baseline to 24 weeks
|
Change in visual acuity
Time Frame: Week 12 and 24
|
The percentage of subjects who gain ≥10 or ≥15 ETDRS letters at week 12 and 24 compared to baseline.
|
Week 12 and 24
|
Central Subfield Thickness
Time Frame: Baseline to week 24
|
Mean change in CST as assessed by SD-OCT at weeks 2, 4, 6, 8, 16, 20, 24 compared to baseline.
|
Baseline to week 24
|
Visual function and quality of life
Time Frame: Baseline, week 12 and week 24
|
Improvement in quality of life as assessed by National Eye Institute Visual Function Questionnaire (NEI VFQ-25) at Week 12, and 24 compared to baseline.
|
Baseline, week 12 and week 24
|
Change in macular leakage
Time Frame: Baseline, week 12 and 24 weeks
|
Percentage of subjects showing change in macular leakage on fluorescein angiography (FA) at week 12 and 24 compared to baseline
|
Baseline, week 12 and 24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in intraocular pressure from baseline
Time Frame: 8, 12 and 24 weeks
|
Monitoring of intraocular pressure
|
8, 12 and 24 weeks
|
Change in BCVA
Time Frame: Weeks 8, 12 and 24
|
Percentage of subjects who lose ≥15 ETDRS letters or more at weeks 8, 12, and 24 compared to baseline
|
Weeks 8, 12 and 24
|
Adverse effects
Time Frame: Weeks 8, 12 and 24
|
Participants will be directly asked at every visit during the drug exposure.
In addition a contact number will be provided to the subjects to call if they experience any adverse affect or if they suspect adverse effect at any time between specific visits.
|
Weeks 8, 12 and 24
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Quan D Nguyen, MD, MSc, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Uveal Diseases
- Macular Degeneration
- Macular Edema
- Edema
- Uveitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- 66881
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uveitis Related Cystoid Macular Edema
-
Medical University of ViennaCompletedUveitis Related Cystoid Macular EdemaAustria
-
Moorfields Eye Hospital NHS Foundation TrustNovartisCompletedUveitis Related Cystoid Macular Edema | Steroid-induced Glaucoma - BorderlineUnited Kingdom
-
Marashi Eye ClinicUnknownDiabetic Macular Edema, Cystoid Macular Edema, Chorodial Neovascularzation, Posterior UveitisSyrian Arab Republic
-
University of Campinas, BrazilCompletedUveitis, Anterior | Cystoid Macular EdemaBrazil
-
Wake Forest UniversityCompletedUveitis | Cystoid Macular EdemaUnited States
-
Oregon Health and Science UniversityWithdrawnUveitis | Cystoid Macular Edema
-
Merck Sharp & Dohme LLCTerminatedUveitis | Cystoid Macular Edema
-
Shahid Beheshti University of Medical SciencesUnknownUveitis | Cystoid Macular EdemaIran, Islamic Republic of
-
National Eye Institute (NEI)Completed
-
National Eye Institute (NEI)Completed
Clinical Trials on OCS-01
-
OculisORA, Inc.RecruitingPain, Postoperative | Cataract | Inflammation EyeUnited States
-
TransMedicsRecruiting
-
TransMedicsActive, not recruiting
-
TransMedicsCompletedOCS Lung SystemUnited States, Germany, Belgium
-
OculisORA, Inc.Active, not recruitingDry Eye DiseaseUnited States
-
Hannover Medical SchoolRecruiting
-
TransMedicsActive, not recruiting